tbuckley/cabot-search huggingface dataset:
AB0693 Demographic, clinical, laboratory and imaging characteristics of an incidence cohort of 93 patients with large vessel gca
Authors: P. Macchioni, L. Boiardi, G. Restuccia, F. Muratore, P. Mancuso, M. Catanoso, C. Salvarani
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Few study have evaluated the clinical and imaging data of patients with large vessel GCA (LVGCA) <h3>Objectives</h3> To evaluate clinical, demographical and imaging data of an inception cohort of 93 patients with LVGCA recruited in Reggio Emilia (Northern Italy) <h3>Methods</h3> All patients with incident large vessel GCA diagnosed between 1 January 2005 and 31 December 2016 and living in the Reggio Emilia area, were identified by capture and re-capture checking of computerised discharge diagnosis codes (ICD10) and using outpatients databases from rheumatology, internal medicine, surgery, pathology, imaging departments of Reggio Emilia Hospital as well as by examining the Reggio Emilia district database for rare diseases. To be included in the study, patients must satisfy the following 2 criteria: Age at disease onset ≥50 years; evidence of large-vessel vasculitis by clinical criteria, angiography, MRA, CTA, PET/CT and/or ultrasonography. Demographic, clinical, laboratory and imaging data collected at first visit were retrived from patients records. <h3>Results</h3> There were 93 incident cases of LV GCA (66 women, 71%) during the 12 year study period; Mean ±SD age at diagnosis was 72±9 years. The three most prevalent signs an symptoms were: systemic in 49 pts (52.7%), GCA cranial symptoms in 39 pts (41.9%) and PMR in 35 pts (37.6%). Peripheral ischaemic symptoms were observed only in 8 pts (8.6%). Forty four pts had temporal artery biopsy and 70.5% resulted positive. At US examination the three most common involved arteries were: common carotid artery (59.2% pts), subclavian artery (53.3% pts) and axillary artery (49.3 pts). At PET/CT scan examination the most common involved arteries were: thoracic aorta (72.1% pts), subclavian artery (61.8% pts) and abdominal aorta (58.8% pts). Celiac trunk and mesenteric artery were involved in 18.4% of pts and renal artery in 10.2% of pts. <h3>Conclusions</h3> In an inception cohort of LVGCA systemic manifestations had the highest prevalence among presenting symptoms. Imaging studies demonstrated an high prevalence of aortic and subclavian involvement. <h3>Disclosure of Interest</h3> None declared
The Misclassification of Diffuse Gliomas: Rates and Outcomes
Authors: J. Bryan Iorgulescu, Matthew Torre, Maya Harary, Timothy R. Smith, Ayal A. Aizer, David A. Reardon, Jill S. Barnholtz-Sloan, Arie Perry
Journal: Clinical Cancer Research (2019)

Abstract Purpose: The integrated histopathologic and molecular diagnoses of the 2016 WHO classification of central nervous system tumors have revolutionized patient care by improving diagnostic accuracy and reproducibility; however, the frequency and consequences of misclassification of histologically diagnosed diffuse gliomas are unknown. Experimental Design: Patients with newly diagnosed ICD-O-3 (International Classification of Diseases) histologically encoded diffuse gliomas from 2010–2015 were identified from the National Cancer Database, the misclassification rates and overall survival (OS) of which were assessed by WHO grade and 1p/19q status. In addition, misclassification rates by isocitrate dehydrogenase (IDH), ATRX, and p53 statuses were examined in an analogous multi-institutional cohort of registry-encoded diffuse gliomas. Results: Of 74,718 patients with diffuse glioma, only 74.4% and 78.8% of molecularly characterized WHO grade II and III oligodendrogliomas were in fact 1p/19q-codeleted. In addition, 28.9% and 36.8% of histologically encoded grade II and III “oligoastrocytomas”, and 6.3% and 8.8% of grade II and III astrocytomas had 1p/19q-codeletion, thus molecularly representing oligodendrogliomas if also IDH mutant. OS significantly depended on accurate WHO grading and 1p/19q status. Conclusions: On the basis of 1p/19q, IDH, ATRX, and p53, the misclassification rates of histologically encoded oligodendrogliomas, astrocytomas, and glioblastomas are approximately 21%–35%, 6%–9%, and 9%, respectively; with significant clinical implications. Our findings suggest that when compared with historical histology-only classified data, in national registry, as well as, institutional databases, there is the potential for false-positive results in contemporary trials of molecularly classified diffuse gliomas, which could contribute to a seemingly positive phase II trial (based on historical comparison) failing at the phase III stage. Critically, findings from diffuse glioma clinical trials and historical cohorts using prior histology-only WHO schemes must be cautiously reinterpreted.
THU0538 Patients with chronic low back painoriented to functional restoration program are younger, with higher smoking and longer sick leave: a cross- sectional study of 166 patients
Authors: M. Assadourian, F. Bailly, P. Letellier, S. Ascione, M. Le Ralle, A. Potel, L. Morardet, V. Foltz, A. Dupeyron, N. Ibrahim, I. Griffoul-Espiltalier, B. Duplan, J. Beaudreuil, B. Fautrel, L. Gossec
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Functional Restoration Programs (FRP) are multi-disciplinary programs that have demonstrated effectiveness to promote functional status and return to work in patients with chronic low back pain (cLBP)<sup>1; 2; 3</sup> and moderate or high disability. <h3>Objectives</h3> To explore the characteristics of cLBP patients oriented or not towards a FRP. <h3>Methods</h3> This was an observational cross-sectional, multi-centric study in France in 2017. Consecutive patients with cLBP (&gt;6 weeks) with or without radiculalgia, aged 18–66 years and visiting the rheumatologist for cLBP were included. Patient and disease characteristics were collected. Patients oriented or not towards a FRP were compared in particular for demographic characteristics, duration of sick leave over the past 12 months, smoking, ongoing aerobic physical activity (patient-reported as &lt;or at least 30 min sessions twice a week), anxiety or depression (Hospital Anxiety and Depression Scale≥11), disability (Oswestry &gt;40%) and kinesiophobia (Tampa Kinesiophobia Scale≥40). <h3>Results</h3> In all, 166 patients were analysed: median age 48 years, median cLBP duration 5 years, and 100 (60%) were females. Overall, 62 (37<i>%)</i> were proposed for a FRP. Patients oriented towards a FRP, versus not, were more frequently male (50% vs 44%, p=0.04), younger (median 46 vs 52 years, p=0.02), and had lower pain levels (median 6 vs 7 of 0–10 numeric scale, p=0.006). They had longer sick leave (mean 18 vs 10 weeks/year, p=0.006), were more frequently smokers (33% vs 23%, p=0.02), had similar pain duration (60 month vs 72, p=0.32), functional disabilities (39% vs 49%, p=0.22), kinesiophobia (62% vs 55%, p=0.65), anxiety (52% vs 55%, p=0.60) and depression score (40% vs 35%, p=0.54), but less physical activity practice (38% vs 54%, p=0.04). <h3>Conclusions</h3> Patients oriented towards a FRP were younger and more often males, with higher smoking and longer sick leave. It appears that kinesiophobia, functional status and duration of low back pain didn't influence the orientation toward a FRP. More comprehensive assessments of patients with cLBP are needed; multifactorial questionnaires such as StartBack or BP2 may be useful to orient patients towards FRPs. <h3>References</h3> [1] Poulain C, et al. Eur Spine J2010Jul;19(7):1153–61. [2] Véron O, et al. Ann Readapt Med Phys2008;51(8):642–9. [3] Roche-Leboucher, et al. Spine2011Dec 15;36(26):2235–42. <h3>Disclosure of Interest</h3> None declared
AB0413 Nodular polyarteritis as an unforeseeable adverse reaction in ra patient treated with tofacitinib
Authors: Y. Muraviev, S. Radenska-Lopovok, V. Lebedeva, S. Alamankina
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Tofacitinib basic prescribing information and guidelines for medical use do not provide any description of such adverse drug reaction (ADR) as vasculitis, in particular polyarteritis nodosa. We present a clinical case of vasculitis emerging during tofacitinib therapy. <h3>Objectives</h3> demonstration of an unexpected reaction to tofacitinib Demonstration of an unexpected reaction to tofacitinib <h3>Methods</h3> A 59 y.o. RA female patient was hospitalised in December 2016 due to eruption of indurated nodules on her hips and legs producing sharp pain, ulceration of nodules on the legs, painful hip and ankle joints, and morning stiffness lasting for about one hour. <h3>Results</h3> Seropositive RA was diagnosed in this patient in April 2004 with subsequent DMARD with methotrexate (MT) at 7,5 mg/week. The remission achieved lasted until November 2005. Gradual dose escalation up to 20 mg/week was required during 2006 in view of RA exacerbations, nevertheless, clinical and lab RA activity persisted. Therefore tofacitinib (Jakvinus) was administered in November 2015 at 10 mg/day, with rapid achievement of minimum RA activity (DAS28=3,0). By the end of May 2016 clinical manifestations of vasculutis emerged, and in June 2016 tofacitinib was discontinued due to increasing lab activity of the disease. Clinical examination: patient's condition is moderately grave. The thinned skin looks dry, showing multiple regenerating ulcers on the anterior leg surface and sharply painful ulcerated indurations on the right inner thigh producing serosanguinous fluid. The RA activity is equal to DAS28=5,72, Hв 125 g/L, WBC 6,0 × 10<sup>9</sup>/L, platelets 40 × 10<sup>9</sup>/L, ESR 22 mm/h, CRP 42 mg/L, RF 413 IU/ml, <i>antibody to cyclic citrullinated peptide</i> (ACPA) is 195 U/ml, TNF – 13,9 pg/ml. Wrist and distal foot radiographs show moderate extended osteoporosis, narrowing of some joint spaces, rare bone and articular surface erosions, subluxation of some joints. Histopathology of skin and subcutaneous fat biopsy samples is presented on figure 1a,1b. Histopathology data suggests the presence of cutaneous and subcutaneous fat productive and destructive vasculitis and acute, predominantly lobular, panniculitis; such structural changes are usually present in cutaneous polyarteritis nodosa and other systemic vasculitis. The casual relationship between this ADR and tofacitinib therapy was assessed as probable using Naranjo scale. <h3>Conclusions</h3> development of vasculitis (polyarteritis nodosa) in RA patient can be caused by tofacitinib. <h3>Disclosure of Interest</h3> None declared
Hypophosphatemia after High Dosage Iron Substitution with Ferric Carboxymaltose (FCM) and Iron Isomaltoside (IM) — the Randomised Controlled Home Afers 1 Trial
Authors: Insa E. Emrich, Fabio Lizzi, Seiler-Mußler Sarah, Christian Ukena, Dominic Kaddu-Mulindwa, Michael Böhm, Stephan Stilgenbauer, Danilo Fliser, Vincent Brandenburg, Gunnar Heine
Journal: Blood (2018)
SAT0524 The role of polymorphisms of hemostasis genes in venous thromboembolic events in anca-associated vasculitides
Authors: E. Makarov, N. Bulanov, P. Novikov, T. Krasnova, A. Balatskiy, L. Samokhodskaya, S. Moiseev
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The role of polymorphisms of hemostasis genes in venous thromboembolic events in ANCA-associated vasculitides. <h3>Objectives</h3> To evaluate the role of polymorphisms of hemostasis genes in the risk of VTEs in AAV patients and to the clinical features of AAV. <h3>Methods</h3> We studied 85 patients with AAV [69 with granulomatosis with polyangiitis (GPA), 11 with microscopic polyangiitis (MPA), 5 with eosinophilic granulomatosis with polyangiitis (EGPA)] diagnosed according to <sup>CHCC 2012</sup> classification. There were 34 males and 51 females, aged of 55<sup>45;63</sup> years. Duration of follow-up was 74.0 (36.5;120.3) months. Coagulation genes polymorphisms MTHFR 677 C/T (rs1801133), <sup>FV 1691</sup> G/A (rs6025), FII 20120 G/A (rs1799963), FGB 455 G/A (<i>rs</i>1800790), PAI-1 675 5G/4G<b> (</b>rs1799889), ITGA2 807 C/T (rs1126643), ITGB3 1565 T/C (rs5918), FVII 10976 G/A (rs6046), FXIII 103 G/T (rs5985) were evaluated by real time polymerase chain reaction. VTEs (deep vein thrombosis, pulmonary embolism) were identified by ultrasonography and chest computed tomography, respectively. We used score system, according to which the presence of each minor allele was assigned one point. <h3>Results</h3> We retrospectively detected 12 (14.1%) VTEs in 85 patients with AAV, including 5 (7.2%) in GPA, 4 (36,4%) in MPA and 3 (60,0%) in EGPA. There were no significant differences in the prevalence of alleles of the each gene in patients with and without VTE (figure 1). However, the combination of integrin A2 (ITGA2 807 C/T), plasminogen activator inhibitor-1 (PAI-1 675 5 G4G), fibrinogen (FGB 455 G/A) and FV<sup>FV 1691</sup> G/A) polymorphisms was associated with a significantly higher occurence of VTE in patients with AAV (p=0.007) (table 1). We observed a higher risk of lung involvement in carriers of methylenetetrahydrofolate reductase gene (MTHFR 677 C/T) polymorphism (p=0.007, OR 4.305 (95% CI 1.55 to 11.98), and an earlier AAV onset in patients with FXIII 103 G/T polymorphism (47.0 vs 50.0 years, p=0.049) <h3></h3> <h3>Conclusions</h3> The combination of several genetic polymorphisms of hemostasis system is associated with an increased prevalence of VTE in AAV patients. The association between MTHFR 677 C/T and FXIII 103 G/T alleles and clinical features of AAV warrants further studies in the larger cohorts of patients. <h3>Acknowledgements</h3> The study was conducted in the framework of Government Assignment of Lomonosow Moscow State University. <h3>Disclosure of Interest</h3> None declared
Drugs for dementia: exercise is medicine
Authors: Damian M Bailey, Thomas A Calverley, Robin Corkill
Journal: BMJ (2019)

Richardson and colleagues found an association between anticholinergic drugs and risk of dementia.1 We appreciate their epidemiological approach but would like to direct some attention towards the mechanistic adaptations that may underlie this association.

The authors correctly allude to neurodegeneration as the pathological process precipitating dementia. But we should also focus on cerebrovascular changes given recent evidence indicating that …
Author Correction: Assembly of a pan-genome from deep sequencing of 910 humans of African descent
Authors: Rachel M. Sherman, Juliet Forman, Valentin Antonescu, Daniela Puiu, Michelle Daya, Nicholas Rafaels, Meher Preethi Boorgula, Sameer Chavan, Candelaria Vergara, Victor E. Ortega, Albert M. Levin, Celeste Eng, Maria Yazdanbakhsh, James G. Wilson, Javier Marrugo, Leslie A. Lange, L. Keoki Williams, Harold Watson, Lorraine B. Ware, Christopher O. Olopade, Olufunmilayo Olopade, Ricardo R. Oliveira, Carole Ober, Dan L. Nicolae, Deborah A. Meyers, Alvaro Mayorga, Jennifer Knight-Madden, Tina Hartert, Nadia N. Hansel, Marilyn G. Foreman, Jean G. Ford, Mezbah U. Faruque, Georgia M. Dunston, Luis Caraballo, Esteban G. Burchard, Eugene R. Bleecker, Maria I. Araujo, Edwin F. Herrera-Paz, Monica Campbell, Cassandra Foster, Margaret A. Taub, Terri H. Beaty, Ingo Ruczinski, Rasika A. Mathias, Kathleen C. Barnes, Steven L. Salzberg
Journal: Nature Genetics (2019)
Abstract 19920: Cardiac Myosin Binding Protein-C Modulates the Cellular Immune Response to Protect the Heart
Authors: Carl W Tong, Giuseppina Dusio, Susannah Rogers, Paola Rosas, Yang Liu, Richard Tobin, M. Karen Newell-Rogers
Journal: Circulation (2017)

Introduction: Sepsis and inflammation can cause cardiac dysfunction. Cardiac myosin binding protein-C (cMyBP-C), a heart muscle thick filament protein, has 8/11 immunoglobulin domains suggesting a potential role in modulating immune function in the heart. Hypothesis: cMyBP-C can modulate the immune response to protect the heart. Methods: Wild type (WT), cMyBP-C(-/-) “KO”, and cMyBP-C(t3SA): cMyBP-C phosphorylation deficient (S273A/S282A/S302A) mice were challenged with 3 intraperitoneal injections of lipopolysaccharide (LPS) over 1 week. Echocardiography and flow cytometric analysis of immune cells (extracted from the heart following isolated heart perfusion) were performed, followed by a proliferation assay to determine the impact of heart leukocytes on splenic proliferative responses. Results: LPS challenge worsened diastolic dysfunction (increasing E/e’) and hypertrophy (increasing posterior wall thickness “PWTd”) only in KO hearts. Because cMyBP-C(t3SA) hearts exhibit both hypertrophy and diastolic dy...
Abstract 14623: Role of Left Atrial Epicardial Adipose Tissue in the Electrophysiologic Substrate for Atrial Fibrillation
Authors: Tarek Zghaib, Sohail Zahid, Esra I Gucuk, Muhammad A Balouch, Satish Misra, Hiroshi Ashikaga, Ronald D Berger, Joseph E Marine, David D Sprang, Stefan L Zimmerman, Natalia Trayanova, Hugh Calkins, Saman Nazarian
Journal: Circulation (2016)

Background: Epicardial adipose tissue (EAdT) appears to contribute to atrial fibrillation (AF) pathogenesis through the release of inflammatory cytokines and its rich innervation with ganglionated ...
Association of Adverse Effects of Medical Treatment With Mortality in the United States
Authors: Jacob E. Sunshine, Nicholas Meo, Nicholas J. Kassebaum, Michael L. Collison, Ali H. Mokdad, Mohsen Naghavi
Journal: JAMA Network Open (2019)

<h3>Importance</h3> More than 20 years have passed since the first publication of estimates of the extent of medical harm occurring in hospitals in the United States. Since then, considerable resources have been allocated to improve patient safety, yet policymakers lack a clear gauge of the progress made. <h3>Objectives</h3> To quantify the cause-specific mortality associated with adverse effects of medical treatment (AEMT) in the United States from 1990 to 2016 by age group, sex, and state of residence and to describe trends in types of harm and associations with other diseases and injuries. <h3>Design, Setting, and Participants</h3> Cohort study using 1990-2016 data on mortality due to AEMT from the Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2016 study, which assessed death certificates of US decedents. <h3>Exposures</h3> Death with<i>International Classification of Diseases</i>(<i>ICD</i>)–coded registration. <h3>Main Outcomes and Measures</h3> Mortality associated with AEMT. Secondary analyses were performed on all<i>ICD</i>codes in the death certificate's causal chain to describe associations between AEMT and other diseases and injuries. <h3>Results</h3> From 1990 to 2016, there were an estimated 123 603 deaths (95% uncertainty interval [UI], 100 856-163 814 deaths) with AEMT as the underlying cause. Despite an overall increase in the number of deaths due to AEMT over time, the national age-standardized mortality rate due to AEMT decreased by 21.4% (95% UI, 1.3%-32.2%) from 1.46 (95% UI, 1.09-1.76) deaths per 100 000 population in 1990 to 1.15 (95% UI, 1.00-1.60) deaths per 100 000 population in 2016. Men and women had similar rates of AEMT mortality, and those 70 years or older had mortality rates nearly 20-fold greater compared with those aged 15 to 49 years (mortality rate in 2016 for both sexes, 7.93 [95% UI, 7.23-11.45] per 100 000 population for those aged ≥70 years vs 0.38 [95% UI, 0.34-0.43] per 100 000 population for those aged 15-49 years). Per 100 000 population, California had the lowest age-standardized AEMT mortality rate at 0.84 deaths (95% UI, 0.57-1.47 deaths), whereas Mississippi had the highest mortality rate at 1.67 deaths (95% UI, 1.19-2.03 deaths). Surgical and perioperative events were the most common subtype of AEMT, accounting for 63.6% of all deaths for which an AEMT was identified as the underlying cause. <h3>Conclusions and Relevance</h3> This study's findings suggest a modest reduction in the mortality rate associated with AEMT in the United States from 1990 to 2016 while also observing increased mortality associated with advancing age and noted geographic variability. The annual GBD releases may allow for tracking of the burden of AEMT in the United States.
Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis
Authors: Madeline Waldron, Caitlin Siebenaller, Brian P. Hobbs, Marc Earl, Mary Schleicher, Hetty E. Carraway, Anjali S. Advani, Aziz Nazha, Aaron T. Gerds, Betty K. Hamilton, Ronald Sobecks, Matt Kalaycio, Mikkael A. Sekeres, Sudipto Mukherjee
Journal: Blood (2018)
Abstract 15016: Calcifications of Aortic Valve, Coronary Arteries and Aorta in 500 Consecutive Patients
Authors: Anna Galas, Ilona Michalowska, Cezary Kepka, Elzbieta Abramczuk, Ewa Orlowska-Baranowska, Tomasz Hryniewiecki
Journal: Circulation (2015)

Introduction: Diseases presenting with cardiac and vascular calcification are well known and a variety of diagnostic modalities enable detection of calcifications. However, the relationship between calcification of arteries and the aortic valve together with corresponding pathophysiological processes have not been yet unequivocally elucidated. Purposes of the study: An assessment of correlation between presence and severity of calcifications in the aortic valve, coronary arteries, aorta and influence of cardiovascular disease risk factors on prevalence of calcifications in this locations. Material and Methods: The study included consecutive patients over 60 years of age referred for computed tomography imaging of coronary artery disease. A total number of included patients reached 500 subjects. Besides coronary artery calcification (CAC), we evaluated aortic valve calcification (AVC) and ascending aorta calcification (AAC). Computed tomography examinations were performed with a dual-source, 64-slice scanner. Exclusion criteria encompassed: diagnosed aortic valve disease, history of coronary artery angioplasty, bypass grafting or heart valve surgery. Results: AVC was diagnosed in 163 patients (32.6%). Prevalence of CAC and AAC was higher than AVC and amounted to 78.8% and 59.8%, respectively. Aortic valve calcification was more often observed in men than women. Degree of AVC severity was significantly lesser than that of CAC and AAC (p=0.0001, p=0.0001). In our study population, we did not find a significant dependence between presence and severity of AVC and CAC or AAC. However, we did observe a statistically significant relationship between presence and severity of CAC and AAC. In contrast to coronary arteries and the aorta, we did not find significantly increased prevalence of AVC among patients with arterial hypertension, dyslipidemias, diabetes, smokers or patients with elevated BMI. Only sex and age exerted significant influence on development of AVC. Conclusions: Despite some similarities between the process of aortic valve calcification and that involving coronary arteries and aorta, these phenomena are not interrelated. It seems that process of calcification of the aortic valve is significantly different from atherosclerosis.
Abstract 19403: Gender and Socioeconomic Disparities With Health Status in Outpatients With Heart Failure: Insights From the CHAMP-HF Registry
Authors: Yevgeniy Khariton, Michael Nassif, Laine Thomas, Gregg C Fonarow, Xiaojuan Mi, Adam DeVore, Carol Duffy, Nancy M Albert, J. Herbert Patterson, Javed Butler, Adrian Hernandez, Fredonia Williams, Stuart Turner, Kevin McCague, John A Spertus
Journal: Circulation (2017)

Introduction: Heart failure with reduced ejection fraction (HFrEF) is a common condition that significantly impacts patients’ health status - their symptoms, function, and quality of life. There ar...